MyMD Pharmaceuticals Enrolls First Individual in Stage 2 Scientific Trial of MYMD-1 as a Therapy for Delaying Aging as well as Expanding Healthy Lifespan

MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals Inc (” MyMD” or “the Company”), a professional phase pharmaceutical company dedicated to extending healthy lifespan, today revealed that the very first client has actually been enrolled in the Business’s Phase 2 professional trial of lead candidate MYMD-1, a dental immune regulator medication, as a therapy for postponing aging and also expanding healthy and balanced lifespan.

The key endpoint for the Phase 2 double-blind, placebo-controlled scientific test is to accomplish a reduction in the distributing degrees of (TNF-α), tumor necrosis variable receptor I (TNFRI) and IL-6. TNF-α and IL-6 are the healthy proteins in the body that create inflammation as well as assist activate the process of aging. The second actions of the test will be the safety, tolerability, and also pharmacokinetics in this populace of people.

” In a Phase 1 professional test of MYMD-1, we demonstrated the drug’s statistically considerable efficiency in minimizing levels of TNF-α, a key player in causing pathological aging, in the blood. The FDA has actually accepted TNF-α reduction as the key endpoint for our Stage 2 research, which we believe positions us well for an effective Phase 2 result,” claimed Chris Chapman, M.D., Head Of State, Supervisor as well as Principal Medical Police Officer of MyMD. “The initiation of individual registration in this study advances our goal to reduce the aging procedure, avoid loss of muscle tissue in aging, limit frailty, and extend healthy lifespan.”

MyMD has specified that there are no FDA-approved medications for treating aging problems as well as expanding healthy life-span humans, a market anticipated to be at least $600 billion by 20251 according to a major investment bank. TNF-α blockers are one of the most prescribed drugs by earnings, a worldwide market of roughly $40 billion per year,2 and, according to Nature Aging journal,3 a downturn in maturing that would raise life span by one year is worth $38 trillion as well as by ten years is worth $367 trillion.

In addition to aging, MYMD-1’s distinctive activity in controling the body immune system and also treating persistent swelling is being developed for the therapy of autoimmune illness, including rheumatoid arthritis (RA), multiple sclerosis (MS), diabetic issues, as well as inflammatory digestive tract illness.

” We intend to begin writing procedures for a Phase 2 pilot research study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman noted. “The climbing frequency of rheumatoid arthritis as well as various other autoimmune and inflammatory illness are driving demand for TNF inhibitors like MYMD-1, and our team believe our orally provided medicine with very reduced toxicity would certainly be turbulent to the $60 billion market for RA if accepted by the FDA for this indicator.”

Rheumatoid joint inflammation influences roughly 40 million individuals globally.4.

About MYMD-1.

Initially developed for autoimmune diseases, MYMD-1’s primary purpose is to reduce the aging procedure, avoid sarcopenia and also frailty, and expand healthy and balanced life expectancy. Since it can cross the blood-brain barrier as well as get to the main nerves (CNS), MYMD-1 is also positioned to be a possible treatment for brain-related conditions. Its device of action and efficiency in diseases consisting of numerous sclerosis (MS) as well as thyroiditis have been researched via partnerships with numerous academic institutions. MYMD-1 is likewise showing promise in pre-clinical research studies as a prospective therapy for blog post- COVID-19 issues and also as an anti-fibrotic and also anti-proliferation therapeutic.

MYMD-1 has actually revealed performance in pre-clinical studies in managing the body immune system by performing as a selective prevention of growth death factor-alpha (TNF-α), a motorist of chronic inflammation. Unlike various other therapies, MYMD-1 has actually been shown in these pre-clinical studies to selectively block TNF-α when it becomes overactivated in autoimmune illness and cytokine storms, but not block it from doing its normal job of being a first -responder to any regular type of modest infection. MYMD-1’s convenience of oral application is one more differentiator compared to currently readily available TNF-α blockers, all of which need delivery by shot or mixture. No authorized TNF prevention has actually ever been dosed by mouth. In addition, the medicine is not immunosuppressive and also has not been shown to trigger the significant negative effects typical with typical therapies that treat inflammation.

About MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a professional phase pharmaceutical business devoted to extending healthy life expectancy, is focused on creating two unique therapeutic platforms that treat the root causes of illness rather than only attending to the symptoms. MYMD-1 is a medicine platform based upon a clinical phase little particle that controls the body immune system to manage TNF-α, which drives persistent inflammation, and various other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to delay aging, boost long life, and also treat autoimmune conditions and also COVID-19- connected clinical depression. The Company’s 2nd drug platform, Supera-CBD, is being developed to treat chronic discomfort, addiction and epilepsy. Supera-CBD is an unique artificial by-product of cannabidiol (CBD) as well as is being created to address and surpass the swiftly growing CBD market, that includes both FDA authorized drugs and CBD items not currently controlled as medications. To find out more, go to